We are live on ! Find out more

Small Cap Biotechnology
Stocks Ranked by
Market Capitalization

Name Market cap Price Price
change %
SRPT icon
26
Sarepta Therapeutics
SRPT
$1.66B
$1.66B $15.68 1.26%
ABCL icon
27
AbCellera Biologics
ABCL
$1.62B
$1.62B $5.31 6.35%
ANAB icon
28
AnaptysBio
ANAB
$1.6B
$1.6B $54.15 1.38%
MLTX icon
29
MoonLake Immunotherapeutics
MLTX
$1.59B
$1.59B $19.02 1.76%
TSHA icon
30
Taysha Gene Therapies
TSHA
$1.59B
$1.59B $5.52 5.32%
INVA icon
31
Innoviva
INVA
$1.58B
$1.58B $21.44 1.13%
RXRX icon
32
Recursion Pharmaceuticals
RXRX
$1.57B
$1.57B $2.96 1.66%
MAZE
33
Maze Therapeutics
MAZE
$1.53B
$1.53B $27.68 0.04%
NTLA icon
34
Intellia Therapeutics
NTLA
$1.5B
$1.5B $10.73 3.33%
SEPN
35
Septerna Inc
SEPN
$1.49B
$1.49B $33.10 1.11%
AVBP icon
36
ArriVent BioPharma
AVBP
$1.48B
$1.48B $31.73 0.6%
VIR icon
37
Vir Biotechnology
VIR
$1.47B
$1.47B $8.69 6.96%
XNCR icon
38
Xencor
XNCR
$1.44B
$1.44B $19.44 0.46%
AKTS
39
Aktis Oncology
AKTS
$1.32B
$1.32B $23.89 0.5%
ABSI icon
40
Absci
ABSI
$1.28B
$1.28B $7.56 6.32%
MNKD icon
41
MannKind Corp
MNKD
$1.28B
$1.28B $4.13 6.17%
ORIC icon
42
Oric Pharmaceuticals
ORIC
$1.25B
$1.25B $12.10 11.1%
ARDX icon
43
Ardelyx
ARDX
$1.24B
$1.24B $5.03 1.95%
IMTX icon
44
Immatics
IMTX
$1.24B
$1.24B $9.08 2.26%
TRAX
45
First Tracks Biotherapeutics
TRAX
$1.24B
$1.24B $35.52 5.63%
AVLN
46
Avalyn Pharma
AVLN
$1.24B
$1.24B $27.95 5.99%
NVAX icon
47
Novavax
NVAX
$1.23B
$1.23B $7.46 4.73%
JBIO
48
Jade Biosciences
JBIO
$1.22B
$1.22B $20.08 2.34%
INBX icon
49
Inhibrx
INBX
$1.2B
$1.2B $81.55 4.06%
CAPR icon
50
Capricor Therapeutics
CAPR
$1.14B
$1.14B $19.70 0.66%
1
2
3 4 5

Small Cap Biotechnology Stocks at a Glance

Biotechnology companies research and develop novel drugs and therapies, often with no products yet on the market. Clinical-trial readouts and regulatory decisions drive binary stock moves, making pipeline breadth, cash runway, and partnership deals the key variables.

There are 180 small cap Biotechnology stocks — companies in the Biotechnology industry with a market cap between $250M and $2B — worth a combined $157B.

The largest by market cap are UroGen Pharma (URGN) at $2B, Mesoblast (MESO) at $1.99B and Palvella Therapeutics (PVLA) at $1.98B.

Among institutional investors, Aktis Oncology (AKTS) drew the most net new fund positions in Q1 2026: 69 funds opened new positions.

  • Combined market cap: $157B across 180 stocks.
  • Small Cap: market cap between $250M and $2B.
  • Largest constituent: UroGen Pharma (URGN), $2B market cap.
  • Most net new fund positions in Q1 2026: Aktis Oncology (AKTS), +69 holders.

Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q1 2026.